Impact assessment

Hereditary tyrosinaemia type 1 screening: impact assessments

Impact assessment and equality impact assessment on screening for hereditary tyrosinaemia type 1 in the NHS Newborn Blood Spot Screening Programme.

From:
Department of Health and Social Care
Published
1 March 2024
This was published under the 2022 to 2024 Sunak Conservative government

Applies to England

Documents

PDF, 648 KB, 45 pages

This file may not be suitable for users of assistive technology.

Request an accessible format.
If you use assistive technology (such as a screen reader) and need a version of this document in a more accessible format, please email [email protected]. Please tell us what format you need. It will help us if you say what assistive technology you use.

Equality impact assessment: screening for hereditary tyrosinaemia type 1 (HT1)

HTML

Details

The UK National Screening Committee (UK NSC) .

The impact assessment covers:

  • the rationale for the intervention (screening for HT1)
  • the evidence base
  • a description and economic assessment of the policy options
  • monetised and non-monetised costs and benefits of each option
  • laboratory requirements
  • a summary of the preferred option

The equality impact assessment covers:

  • policy objectives
  • who is affected
  • the evidence considered
  • engagement with stakeholders
  • a summary of the analysis and potential impacts

Contact [email protected] for any queries on these publications, making sure you include the full title.

Updates to this page

Published 1 March 2024

Sign up for emails or print this page